» Articles » PMID: 23529397

Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: the Norwegian ParkWest Study

Overview
Journal JAMA Neurol
Date 2013 Mar 27
PMID 23529397
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Mild cognitive impairment (MCI) is common in Parkinson disease (PD), but the prognostic value of MCI in early PD is unknown.

Objective: To examine the course of MCI and its progression to dementia in an incident PD cohort.

Design: Prospective longitudinal cohort study.

Setting: The Norwegian ParkWest study, an ongoing population-based study of the incidence, neurobiology, and prognosis of PD in western and southern Norway.

Participants: A population-based cohort of 182 patients with incident PD monitored for 3 years.

Main Outcomes And Measures: Serial neuropsychological tests of attention, executive function, verbal memory, and visuospatial skills were administered at baseline, 1 year, and 3 years. Patients were classified as having MCI and received a diagnosis of dementia according to published consensus criteria.

Results: Significantly more patients with MCI than without MCI at baseline (10 of 37 [27.0%] vs 1 of 145 [0.7%]; relative risk, 39.2 [95% CI, 5.2-296.5]; P < .001) progressed to dementia during follow-up. Of those with MCI at baseline, 8 of 37 (21.6%) had MCI that reverted to normal cognition during follow-up. Mild cognitive impairment at the 1-year visit was associated with a similar progression rate to dementia (10 of 36 patients [27.8%]) and reversion rate to normal cognition (7 of 36 [19.4%]). However, among the 22 patients with persistent MCI at baseline and the 1-year visit, 10 (45.5%) developed dementia and only 2 (9.1%) had MCI that reverted to normal cognition by the end of study.

Conclusions And Relevance: Mild cognitive impairment at PD diagnosis predicts a highly increased risk for early dementia. Repeated neuropsychological testing increases the prognostic accuracy of MCI with respect to early dementia development in PD.

Citing Articles

Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson's disease.

Gu L, Zhang P, Zuo W, Shu H, Wang P Neurol Sci. 2025; .

PMID: 39924625 DOI: 10.1007/s10072-025-08014-z.


Diagnostic values of serum levels of α-synuclein, homocysteine and leucine-rich α2 glycoprotein for predicting cognitive impairment in Parkinson's disease.

Li R, Zhuang J Acta Neurol Belg. 2024; .

PMID: 39738968 DOI: 10.1007/s13760-024-02710-x.


α-Synuclein Oligomers in Skin Biopsies Predict the Worsening of Cognitive Functions in Parkinson's Disease: A Single-Center Longitudinal Cohort Study.

Contaldi E, Basellini M, Mazzetti S, Calogero A, Colombo A, Cereda V Int J Mol Sci. 2024; 25(22).

PMID: 39596242 PMC: 11594322. DOI: 10.3390/ijms252212176.


Air pollution: a latent key driving force of dementia.

Mohammadzadeh M, Khoshakhlagh A, Grafman J BMC Public Health. 2024; 24(1):2370.

PMID: 39223534 PMC: 11367863. DOI: 10.1186/s12889-024-19918-4.


Screening for Cognitive Impairment in Movement Disorders: Comparison of the Montreal Cognitive Assessment and Quick Mild Cognitive Impairment Screen in Parkinson's Disease and Lewy Body Dementia.

OCaoimh R, Foley M, Timmons S, Molloy D J Alzheimers Dis Rep. 2024; 8(1):971-980.

PMID: 39114555 PMC: 11305847. DOI: 10.3233/ADR-230207.